Author: Editor

Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced the launch of the newest addition to its comprehensive genomic profiling offerings, MI GPSâ„¢ (Genomic Profiling Similarity) Score. MI GPS Score is an AI driven tumor type biology similarity score that uses more than 6500 mathematical models in the machine learning algorithm to compare molecular characteristics of a patient’s tumor against Caris’ extensive database to provide new insights into the molecular subtype of cancer of unknown primary (CUP) cases, atypical clinical presentation cases, and other difficult to treat cancer cases, to…

Combination of Defactinib and CH5126766 Shows Promise in Treating KRAS Mutant Solid Tumors in Clinical Trial Clinical Data Presentation and Regulatory Discussions Planned for 1H 2020 Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today announced a global licensing agreement with Chugai Pharmaceutical Co., Ltd., (Chugai) whereby Verastem Oncology is obtaining worldwide development and commercialization rights to the RAF/MEK inhibitor CH5126766 (CKI27) from Chugai currently under development for the treatment of KRAS mutant solid tumors. The Company will host an investor…

More central line-associated blood infections and catheter malfunctions seen with PICCs A new study provides convincing evidence that the use of peripherally inserted central catheters (PICCs) to administer medicine and draw blood in children is associated with a significantly increased risk of blood clots (known as venous thromboembolism or VTE) compared with central venous catheters (CVCs) placed directly into the neck or chest. The study results, published today in Blood, also reveal a significantly higher rate of CVC-related bloodstream infections and catheter malfunctions among pediatric patients receiving PICCs. Based on the findings, researchers are voicing concerns about the growing use of PICCs –…

Hans Hammers, MD of UT Southwestern Medical Center discusses the role of radiation in kidney cancer at the KCA 2019.

Source: https://www.spreaker.com/user/cancergrace/narjust-duma-md-introduces-cancer-myths- GRACE is excited to bring to you a new series on Cancer Myths in the Latin Community. Our friend and partner, Narjust (N.J.) Duma, MD is a Chief Hematology/Medical Oncology Fellow at Mayo Clinic in Rochester, MN. Dr. Duma is committed to her research and advocacy in diversity and inclusion. She was recognized as the 2018 resident of the year by the National Hispanic Medical Association. N.J. speaks to cancer myths in the Latino community, and in this video N.J. introduces herself and the following series. See more at cancerGRACE.org.

GRACE is very excited to bring you more of our program on supportive care in cancer treatment.Arjun Gupta, MD, one of the GRACE Fellows Ambassador Program Winners for 2019 is the host of this video series, Supportive Care in Cancer Treatment. In this video, Dr. Gupta’s guest is Dr. Dawn Hershman, with Columbia University in New York. Their topic of discussion is Aromatase Inhibitor Induced Arthralgia (AI Induced Arthralgia).For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

Thank you all for joining us for our live stream today! If you have questions please feel free to email us at info@cancerGRACE.org, or go to our community forum at https://cancergrace.org/forum.

GRACE is excited to bring you new information in our Bladder Cancer Program. For this first video of 2019, Dr. Ramy Sedhom introduces us to Dr. Elizabeth Plimack with Fox Chase Cancer Center. Dr. Plimack offers information on the role of immunotherapy in bladder cancer. For more, please visit http://cancerGRACE.org/. For questions or to join the conversation, visit https://cancergrace.org/forum.

GRACE is excited to bring to our Spanish speaking community information on Cancer Basics.Our friend and partner, Narjust (N.J.) Duma, MD is a Chief Hematology/Medical Oncology Fellow at Mayo Clinic in Rochester, MN. Dr. Duma is committed to her research and advocacy in diversity and inclusion. She was recognized as the 2018 resident of the year by the National Hispanic Medical Association.Dr. Duma discusses cancer basics for the Latino community, and in this video N.J. discusses the basics of immunotherapy.Stay tuned for more great videos!If you want to join the conversation, please visit our forums! For more, please visit http://cancerGRACE.org/.…

Androgen Deprivation Therapy (ADT) for Men with Prostate Cancer GRACE is very excited to bring to more info from our new program, Supportive Care in Cancer Treatment. Ramy Sedhom, MD, with Johns Hopkins in Baltimore, Maryland, hosts this episode of Supportive Care in Cancer Treatment. In this video Dr. Sedhom and his guest, Dr. Tyler Stewart with the Moores Cancer Center, UC San Diego, discuss Androgen Deprivation Therapy or ADT for men with prostate cancer. To join the conversation, visit https://cancergrace.org/forum. To find additional CancerGRACE resources, visit https://cancergrace.org. To donate to CancerGRACE, visit https://cancergrace.org/donate.

GRACE is excited to bring you new information in our Bladder Cancer Program. For this video, Dr. Ramy Sedhom introduces us to Dr. Matthew Galsky with the Tisch Cancer Institute and Icahn School of Medicine at Mt. Sinai in New York. Dr. Galsky discusses information on the role of immunotherapy in metastatic bladder cancer.For more, please visit http://cancerGRACE.org/. For questions or to join the conversation, visit https://cancergrace.org/forum.

Dr. Duma is an Assistant Professor and Thoracic Oncologist at @UWcarbone, University of Wisconsin Carbone Cancer Center, and Former Chief Fellow @MayoClinic in Rochester, Minnesota. We are pleased to present more information for the Latino community on cancer basics. In this video Dr. Duma speaks with Dr. Maria Daniela Martin, and discusses the basics of immunotherapy. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

Ramon Parsons, MD, PhD @Ramon_Parsons of @IcahnMountSinai discusses a novel agent that degrades a protein called EZH2 that drives the growth of triple negative breast cancer in cancer cell lines and live models. This research also showed that the agents which inhibit the enzymatic activity of EZH2 but do not degrade EZH2 did not work in triple negative breast cancer.

·         At the planned interim analysis, Phase III JAVELIN Bladder 100 study met the primary endpoint of prolonging overall survival (OS) as a first-line maintenance treatment versus standard of care ·         BAVENCIO is the first immunotherapy to significantly prolong OS in locally advanced or metastatic urothelial carcinoma (UC) in the first-line setting in a Phase III trial   EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer Inc. (NYSE: PFE) today announced the Phase III JAVELIN Bladder 100 study met its primary endpoint of overall survival (OS) at the planned interim analysis. In this…

Ramon Parsons, MD, PhD @Ramon_Parsons of @IcahnMountSinai discusses a novel agent that degrades a protein called EZH2 that drives the growth of triple negative breast cancer in cancer cell lines and live models. This research also showed that the agents which inhibit the enzymatic activity of EZH2 but do not degrade EZH2 did not work in triple negative breast cancer.

The Department of Neurosurgery at the Icahn School of Medicine at Mount Sinai has received more than $10 million in federal funding for several projects focusing on brain tumor research. The newest grant focuses on the use of magnetic hyperthermia therapy (MHT), a powerful nanotechnology-based treatment that may enhance the effects of radiation therapy and chemotherapy on glioblastoma tumors. The lead investigator is Constantinos Hadjipanayis, MD, PhD, Director of Neurosurgical Oncology at the Mount Sinai Health System and Chair of Neurosurgery at Mount Sinai-Union Square. “Our neurosurgeons are at the forefront of clinical care and scientific research with the goal…

– Data from pivotal study demonstrate safety and efficacy regardless of prior gastrectomy in previously treated patients with metastatic gastric cancer (mGC) and gastroesophageal junction (GEJ) adenocarcinoma   PRINCETON, N.J., October 14, 2019 – Taiho Oncology, Inc. announced today that detailed results from the analysis of patients with prior gastrectomy enrolled in the Phase 3 TAS-102 Gastric Study (TAGS) evaluating LONSURF® (trifluridine and tipiracil) in adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy, were published in the…

Betty Hamilton, MD of @ClevelandClinic discusses the post-transplant work statue of young adult survivors of allogeneic hematopoietic cell transplant.

Abby Statler, MD of @ClevelandClinic answers if racial disparities in AML are associated with organ dysfunction.

Ajay K. Nooka, MD of @WinshipAtEmory discusses multiple myeloma disparities.

Robert Kreitman, MD of National Cancer Institute discusses Lumoxiti® phase III trial in patients with relapsed or refractory hairy cell leukemia.

Allison M. Winter, MD of @ClevelandClinic discusses comparative outcomes of relapsed follicular lymphoma patients treated with novel agents.

Hope Rugo, MD of @UCSFMedicine discusses the SOPHIA Study. _____________ MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today presented updated results from the Phase 3 SOPHIA study comparing margetuximab plus chemotherapy versus trastuzumab plus chemotherapy in patients with HER2-positive metastatic breast cancer who have previously been treated with anti-HER2-targeted therapies. Margetuximab is an investigational, immune-enhancing monoclonal antibody derived from the Company’s proprietary Fc-engineering technology platform. The data were presented today during an oral session at the San Antonio Breast Cancer Symposium (SABCS) by Dr. Hope Rugo, M.D.,…

MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today presented updated results from the Phase 3 SOPHIA study comparing margetuximab plus chemotherapy versus trastuzumab plus chemotherapy in patients with HER2-positive metastatic breast cancer who have previously been treated with anti-HER2-targeted therapies. Margetuximab is an investigational, immune-enhancing monoclonal antibody derived from the Company’s proprietary Fc-engineering technology platform. The data were presented today during an oral session at the San Antonio Breast Cancer Symposium (SABCS) by Dr. Hope Rugo, M.D., Director, Breast Oncology and Clinical Trials Education, University of California San…

Luca Malorni, MD of Prato Hospital discusses a marker in operable breast cancer at SABCS 19. __________ The study is a retrospective analysis on serum samples from a randomized clinical trial comprising 644 women with operable breast cancer (premenopausal with stage II-IIIB HR+ breast cancer). Serum samples were collected pre-operatively on the day of surgery. After five years, patients with low pre-operative DiviTum values (the lowest quartile, <25 percent) showed a disease-free survival rate of 81 percent versus 58 percent in the group with the highest DiviTum values (>75 percent). “We are thrilled to see these new, interesting results. It…

Luca Malorni, MD of Prato Hospital discusses a marker in operable breast cancer at SABCS 19. __________ The study is a retrospective analysis on serum samples from a randomized clinical trial comprising 644 women with operable breast cancer (premenopausal with stage II-IIIB HR+ breast cancer). Serum samples were collected pre-operatively on the day of surgery. After five years, patients with low pre-operative DiviTum values (the lowest quartile, <25 percent) showed a disease-free survival rate of 81 percent versus 58 percent in the group with the highest DiviTum values (>75 percent). “We are thrilled to see these new, interesting results. It…

Jennifer Crozier, MD of @BaptistHealthSA discusses the FLEX real world data in early stage breast cancer.

William Audeh, MD of @Agendia discusses new data presented at SABCS demonstrating how genomic profiling benefits early stage breast cancer.

Jay Andersen, MD of Compass Oncology discusses the phase 3 KEYNOTE-522 trial was investigating KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 immunotherapy, in combination with chemotherapy that was designed for patients with TNBC.         pembrolizumab, keytruda, phase 3, keynote-522 trial, merck’s anti-pd-1 immunotherapy, immunotherapy, patients with tnbc, tnbc

Rafella Colombatti of University of Padova discusses the European perspective on sickle cell research.

Andrew Campbell, MD of Children’s National Hospital discusses the CASiRE study.

Peter Voorhees, MD of @LevineCancer discusses the depth of response to dara, lenalidomide, bortezomib, and dexamethasone (RVd) improves over time in patients with transplant-eligible newly diagnosed multiple myeloma: GRIFFIN study update.

Timothy Illidge, MD, PhD of @OfficialUoM provides analysis of brentuximab vedotin plus CHP (A+CHP) in the frontline treatment of patients with CD30+ peripheral T-Cell lymphomas (ECHELON-2).

Tanya Siddiqi, MD of @cityofhope discusses the updated results from transcend CLL 004, a Phase 1/2 study including patients with high-risk disease treated with ibrutinib.

Chadi Nabhan, MD MBA of Aptitude Health discusses potential of biosimilars in treatment of blood cancer.

– Jazz to pay an upfront payment of $200 million to PharmaMar – Opportunity for Jazz to expand its oncology portfolio with lurbinectedin, a late stage asset in relapsed small cell lung cancer (SCLC) – PharmaMar is also eligible to receive up to $800 million in potential milestone payments in addition to royalties on net sales – Lurbinectedin New Drug Application (NDA) submitted to FDA in December 2019 with the potential to launch in 2020 Collaboration emphasizes Jazz and PharmaMar’s commitments to providing differentiated medicines to patients in areas of high unmet need PharmaMar (MSE:PHM) and Jazz Pharmaceuticals plc (Nasdaq:JAZZ) today announced that PharmaMar…

Shyamala Navada, MD of @MountSinaiNYC discusses the phase II study of oral rigosertib combined with azacitidine as first line therapy in patients with HR-MDS.

Jeff Sharman, MD of @TheUSONetwork discusses the phase III ELEVATE TN trial. _______ Read here: https://www.oncologytube.com/video/calquence-significantly-prolonged-the-time-patients-lived-without-disease-progression-or-death-in-previously-untreated-chronic-lymphocytic-leukemia?channelName=Cancer-News

Full results from Phase III ELEVATE TN trial showed 93% of patients on CALQUENCE combined with obinutuzumab vs. 47% of patients on chlorambucil plus obinutuzumab remained free of disease progression or death at 24 months Trial also showed 87% of patients on CALQUENCE alone remained free of disease progression or death at 24 months AstraZeneca today presented results from the interim analysis of the Phase III ELEVATE TN trial, showing that CALQUENCE® (acalabrutinib) combined with obinutuzumab or as monotherapy significantly improved progression-free survival (PFS) compared to chlorambucil plus obinutuzumab, a standard chemo-immunotherapy treatment, in patients with previously untreated chronic lymphocytic leukemia…

Saro Armenian, DO of @cityofhope discusses the long term morbidity by survivors of AML treated with blood or marrow transplantation.

Professor Simon Rule of Plymouth University Medical School discusses long term outcomes with ibrutinib versus the prior regimen.

Roman Hajek, MD of University of Ostrava discusses MM patients remaining under represented in clinical trials based on standard laboratory parameters.

Robert Rifkin, MD of @TheUSONetwork discusses the Lyra study.

Aziz Nazha, MD of @CleClinicMD discusses a personalized prediction model to risk stratify patients with AML.

Mohamed Zaki, MD of @abbvie discusses the phase 3 MURANO trial. ________ Read here: https://www.oncologytube.com/video/new-long-term-data-continues-to-demonstrate-progression-free-survival-and-overall-survival-benefits-with-venclexta-venclyxto-venetoclax-combination-in-patients-with-relapsed-refractory-ch-1

Four-year updated analysis from the MURANO trial showed an 81% reduction in the risk of disease progression or death in patients treated with VENCLEXTA®/VENCLYXTO® (venetoclax) plus rituximab (VenR) and higher rates of minimal residual disease (MRD)-negativity compared to bendamustine plus rituximab (BR)[1] – The risk of death was decreased by 59% in the 130 patients who completed VenR, versus BR, despite 79% of patients in the BR arm who went on to receive a novel targeted treatment. Median overall survival (OS) was not reached for either treatment group[1] – Sixty-eight percent of the 130 patients who completed the treatment course…

Michael Wang, MD @michaelwangmd of @MDAndersonNews discusses KTE-X19, an anti-CD19 chimeric antigen receptor (CAR) T cell therapy, in patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL): results of the phase 2 ZUMA-2 study.

Jesus Berdeja, MD @BerdejaJesus of Sarah Cannon Center for Blood Cancers discusses the phase 1 clinical study of bb21217.

Jan G. J. van de Winkel, Ph.D of @Genmab announces data to be presented at ASH 2019 including data from ongoing phase I DuoBody®-CD3xCD20 (GEN3013) trial.

Jan Hillson, MD of @AlpineImmuneSci disucsses ALPN-101.